KR20220103111A - 이상 줄기 세포를 표적으로 하는 당뇨병 치료 - Google Patents

이상 줄기 세포를 표적으로 하는 당뇨병 치료 Download PDF

Info

Publication number
KR20220103111A
KR20220103111A KR1020227016609A KR20227016609A KR20220103111A KR 20220103111 A KR20220103111 A KR 20220103111A KR 1020227016609 A KR1020227016609 A KR 1020227016609A KR 20227016609 A KR20227016609 A KR 20227016609A KR 20220103111 A KR20220103111 A KR 20220103111A
Authority
KR
South Korea
Prior art keywords
diabetes
cells
aberrant
stem cells
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227016609A
Other languages
English (en)
Korean (ko)
Inventor
히데토 코지마
토모야 테라시마
미와코 카타기
Original Assignee
가부시키가이샤 바이오지프코드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 바이오지프코드 filed Critical 가부시키가이샤 바이오지프코드
Publication of KR20220103111A publication Critical patent/KR20220103111A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227016609A 2019-10-18 2020-10-16 이상 줄기 세포를 표적으로 하는 당뇨병 치료 Pending KR20220103111A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019191363 2019-10-18
JPJP-P-2019-191363 2019-10-18
PCT/JP2020/039044 WO2021075535A1 (ja) 2019-10-18 2020-10-16 異常幹細胞を標的とする糖尿病治療

Publications (1)

Publication Number Publication Date
KR20220103111A true KR20220103111A (ko) 2022-07-21

Family

ID=75538122

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227016609A Pending KR20220103111A (ko) 2019-10-18 2020-10-16 이상 줄기 세포를 표적으로 하는 당뇨병 치료

Country Status (7)

Country Link
US (1) US20230025003A1 (https=)
EP (1) EP4035679A4 (https=)
JP (2) JPWO2021075535A1 (https=)
KR (1) KR20220103111A (https=)
CN (1) CN114828891A (https=)
AU (1) AU2020368759A1 (https=)
WO (1) WO2021075535A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671936A1 (en) * 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
WO2004009776A2 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
DE602004032457D1 (de) * 2003-11-07 2011-06-09 Novartis Ag Nten
US9408816B2 (en) * 2006-12-26 2016-08-09 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
WO2010053316A2 (en) * 2008-11-06 2010-05-14 Snu R&Db Foundation New use of sixth immunoglobulin-like domain of vcam-1
WO2011049412A2 (en) * 2009-10-23 2011-04-28 Hanwha Chemical Corporation Human recombinant monoclonal antibody that specifically binds to vcam-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells
CN105640944A (zh) * 2014-12-02 2016-06-08 杨美宁 一种降低2型糖尿病合并冠心病患者sVCAM-1的方法
US10465003B2 (en) * 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JP2019191363A (ja) 2018-04-25 2019-10-31 京セラドキュメントソリューションズ株式会社 定着装置及び画像形成装置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
비특허문헌 1: 당뇨병 진료 가이드라인 2016, 일본 당뇨병 학회, 난코도

Also Published As

Publication number Publication date
CN114828891A (zh) 2022-07-29
WO2021075535A1 (ja) 2021-04-22
US20230025003A1 (en) 2023-01-26
JP2025157483A (ja) 2025-10-15
EP4035679A1 (en) 2022-08-03
EP4035679A4 (en) 2024-08-07
AU2020368759A1 (en) 2022-05-19
JPWO2021075535A1 (https=) 2021-04-22

Similar Documents

Publication Publication Date Title
Iwata et al. Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy
JP6254125B2 (ja) 蛋白尿腎疾患の病因における可溶性ｕＰＡＲの役割
Lucas et al. Inhibition of transforming growth factor-β signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart
JP2023139101A (ja) 幹細胞遊走剤を使用した糖尿病治療
JP6830458B2 (ja) 疾患および障害を検出、治療、および予防するための組成物および方法
KR20230152099A (ko) 당뇨병 및 합병증의 신규 치료, 진단 및 검출을 위한 방법 및 제제
WO2011054644A1 (en) A low density lipoprotein-related protein 1 splice variant as cancer marker
Ablooglu et al. Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease
Li et al. Phosphodiesterase-5a knock-out suppresses inflammation by down-regulating adhesion molecules in cardiac rupture following myocardial infarction
JP2019182873A (ja) 膵臓炎、腎損傷および腎臓癌を治療および予防するための組成物および方法
TWI359271B (en) Pharmaceutical composition for insulin resistance
US20110014215A1 (en) Granulysin and uses thereof
KR20220103111A (ko) 이상 줄기 세포를 표적으로 하는 당뇨병 치료
Sonner et al. A GDF-15–GFRAL axis controls autoimmune T cell responses during neuroinflammation
HK40073293A (en) Diabetes therapy targeting abnormal stem cells
HK40073547A (en) Therapy for diabetes using stem cell migration agent
Preval Transcriptomic and Therapeutic Insights in ADPKD Identify Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) as a Cyst-Specific Target
JP5830329B2 (ja) 腎障害の新規マーカー
HK40074315A (en) Therapy for diabetes using stem cell migration agent
CA2801162A1 (en) Diagnostic, screening and therapeutic applications of ocab-based tools
Vuchkovska Polycystin-2 Is Cardioprotective Against Myocardial Infarction by Regulating the Calcium-Mediated ER-Stress Response
WO2023074794A1 (ja) Ｈｄａｃ調節剤による糖尿病ならびに合併症の治療方法または治療剤
Wu et al. Dapagliflozin targets RORγt to improve myocardial ischemia-reperfusion injury-induced heart failure by regulating the CD4+ T cell/Th17 cell axis within cardiac tissue
JP2024163554A (ja) 同種抗体検出方法、検査方法、検出試薬、検出試薬の製造方法、同種抗体検出キット、及び白血病用医薬

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000